**CPC-032** CLOPIDOGREL FOR THE TREATMENT OF CHILDREN WITH A SYSTEMIC-TO-PULMONARY ARTERIAL SHUNT

doi:10.1136/ejhpharm-2013-000276.489

1A Garzone, 1F Ciuccarelli, 1A Pompilio, 1E Andresciani, 2F Pinto, 2MS De Meo, 1MC Cerlesi, 1P Colonna, 1E Franchi, 1V Moretti, 1L Carlitti, 1P Marzioni, 1M Buccolim, 1AO Ospedali Riuniti – Presidio G. Salesi, Farmacia, Ancona, Italy; 2Università degli Studi di Camerino, Scuola di Specializzazione in Farmacia Ospedaliera, Camerino, Italy; 2AO Ospedali Riuniti – Presidio G.M. Lancisi, Cardiologia e Cardiologia Pediatrica e Congenita, Ancona, Italy

**Background** Clopidogrel is a thienopyridine drug that acts by binding selectively and irreversibly to the adenosine diphosphate (ADP) receptor on platelets. Platelet aggregation is consequently inhibited. Clopidogrel is used to prevent ischemic events in patients at risk, when other drugs fail or are not tolerated. Paediatric use is not authorised because of limited information about efficacy and safety.

**Purpose** To illustrate our experience in the three-month use of clopidogrel in children with a systemic-to-pulmonary arterial shunt, prior to definitive surgical intervention.

**Materials and Methods** On February 2012 a temporary systemic-to-pulmonary arterial shunt was placed in a four-month-old patient, affected by Tetralogy of Fallot with hypoplasia of the infundibulum and pulmonary valve. We administered two antiaggregant drugs, ASA 18 mg and clopidogrel 0.2 mg/Kg once a day, because of the high risk of thrombotic closure of the shunt. We chose an experimental preparation of type 5 capsules with lactose as a diluent. After that, four other children (from 2 months to 4 years old) were treated with clopidogrel, mostly in association with ASA or together with enoxaparin.

**Results** We prepared capsules from 0.75 to 3.5 mg. For all patients we obtained authorization by the Ethics Committee and the patient’s informed consent. After surgery, the children were observed for 7–8 days depending on clinical follow up and complications. We checked the blood count and shunt patency with clinical observation, analysis and echocardiogram. After discharge, patients were first recalled 10–15 days later, then after 1–2 months to see the doctor, have an ECG, blood tests and echocardiogram. Pt was not necessary. No serious side effects were observed.

**Conclusions** Paediatric clopidogrel treatment is rapidly increasing. A wider number of cases, a comparison with other professional experience, and, most of all, controlled clinical trials, would be desirable. No conflict of interest.

**CPC-033** COMPARING EFFECTIVENESS OF FIRST-LINE DISEASE MODIFYING DRUGS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS

doi:10.1136/ejhpharm-2013-000276.490

H Esteban-Cartelle, E Espino-Paisan, C Crespo-Diz, T Rodriguez-Jato, P Suarez Artme. Complejo Hospitalario Universitario de Santiago de Compostela, Pharmacy, Santiago de Compostela, Spain

**Background** Immunomodulatory drugs represent the best therapeutic option in first-line treatment of relapsing-remitting multiple sclerosis (RRMS). This group includes glatiramer acetate (GA) and three formulations of Interferon β (IFNB): subcutaneous IFNB1a (scIFNB1a), intramuscular IFNB1a (imIFNB1a) and subcutaneous IFNB1b (scIFNB1b). Several studies have reported similar efficacy among IFNB and GA preparations, while other have concluded that some differences exist between them.

**Purpose** To compare the effectiveness of first-line disease modifying drugs (FL-DMD) in patients with RRMS.

**Materials and Methods** In this retrospective and observational study we included treatment-naïve patients with RRMS who had started treatment with FL-DMD between 1996 and 2011. Patients receiving other immunosuppressant drugs were excluded. Data were collected from medical records and pharmacy computer applications. Patients were classified in four groups: those treated with imIFNB1a, scIFNB1a, scIFNB1b or GA. The annualised relapse rate (ARR) and degree of disability for each group were determined in the pre-treatment and treatment periods. The time to first relapse (TFR), proportion of relapse-free patients (RFP) and proportion of patients without progression of disability (DPPF) in each group were compared.

**Results** We identified 72 patients who had started treatment with DMD: 22 with imIFNB1a, 13 with scIFNB1a, 26 with scIFNB1b and 11 with AG.

Mean ARR in the pre-treatment and treatment periods were the following (mean±SD): 0.75 ± 0.40 and 0.10 ± 0.16 for imIFNB1a, 0.81 ± 0.45 and 0.21 ± 0.32 for scIFNB1a, 0.56 ± 0.33 and 0.11 ± 0.20 for scIFNB1b and 0.73 ± 0.34 and 0.17 ± 0.28 for GA. TFR in each group were respectively 5.8 ± 4.2, 3.8 ± 2.5, 5.3 ± 3.8 and 2.4 ± 1.6 years. We found 59.1%, 61.5%, 61.5% and 63.6% RFP in each group and 90.9%, 92.3%, 88.5% and 81.3% DPPF respectively. No statistical differences were found in TFR, RFP or DPPF among groups.

**Conclusions** No differences were found among the different first-line treatment options in terms of reduction of disease activity or progression of disability. No conflict of interest.

**CPC-034** COMPARISON OF EFFECTIVENESS AND SAFETY OF PRIMARY PROPHYLAXIS WITH BIOSIMILAR FILGRASTIM VS REFERENCE MEDICINAL PRODUCT IN PATIENTS TREATED WITH R-CHOP

doi:10.1136/ejhpharm-2013-000276.491

M Hudson, V Domingos, A Melo Gouveia. Instituto Português Oncologia Lisboa, Pharmacy, Lisbon, Portugal

**Background** Prophylactic administration of filgrastim can reduce the risk of febrile neutropenia (FN) in oncological patients undergoing myelosuppressive chemotherapy.

According to approved guidance on biosimilar drugs, clinical comparability can be obtained from results extrapolated from other indications.

Due to this simplified pathway, concerns about safety and effectiveness in some clinical settings may remain.

**Purpose** To compare the effectiveness and safety of biosimilar filgrastim (B) with the reference medicinal product (RMP) in patients with haematological malignancies treated with the R-CHOP regimen and undergoing primary prophylaxis (PP) with filgrastim.

**Materials and Methods** A single-centre, retrospective and transversal study was performed: from March 2010 to October 2010 (RMP) and March 2011 to February 2012 (B).

Main endpoints were incidence of FN (per patient and per cycle), time to absolute neutrophil count (ANC) recovery, incidence of NP in first cycle (1stCy), number of hospitalisation days related to FN. Other endpoints and patient-related risk factors for FN were evaluated.

**Results** The results seem to support equivalence of effectiveness between these drugs. We did not find any safety-related incidents. More patients are being included to increase the sample size and allow statistical significance. These results may further support the use of the more cost-efficient option.

No conflict of interest.